The estimated Net Worth of Jacob Waugh is at least $2.8 Milhão dollars as of 17 September 2014. Jacob Waugh owns over 97,713 units of Revance Therapeutics Inc stock worth over $164,500 and over the last 11 years Jacob sold RVNC stock worth over $2,637,340.
Jacob has made over 2 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jacob sold 97,713 units of RVNC stock worth $2,025,590 on 17 September 2014.
The largest trade Jacob's ever made was selling 97,713 units of Revance Therapeutics Inc stock on 17 September 2014 worth over $2,025,590. On average, Jacob trades about 24,543 units every 6 days since 2014. As of 17 September 2014 Jacob still owns at least 25,000 units of Revance Therapeutics Inc stock.
You can see the complete history of Jacob Waugh stock trades at the bottom of the page.
Jacob's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, eAngus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: